These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 17075587)

  • 41. [Prostate specific antigen: utilization modalities and interpretation].
    Hannoun-Levi JM; Ginot A; Thariat J
    Cancer Radiother; 2008 Dec; 12(8):848-55. PubMed ID: 18539498
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer.
    Maffezzini M; Bossi A; Collette L
    Eur Urol; 2007 Mar; 51(3):605-13; discussion 613. PubMed ID: 17113217
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.
    Stock RG; Klein TJ; Cesaretti JA; Stone NN
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):753-8. PubMed ID: 19084351
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen.
    Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
    Jpn J Clin Oncol; 2008 Jan; 38(1):36-42. PubMed ID: 18258713
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.
    Ryan CJ; Harzstark AH; Rosenberg J; Lin A; Claros C; Goldfine ID; Kerner JF; Small EJ; Youngren JF
    BJU Int; 2008 Feb; 101(4):436-9. PubMed ID: 18234062
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
    Banu E; Banu A; Medioni J; Levy E; Thiounn N; Mejean A; Andrieu JM; Oudard S
    Prostate; 2007 Oct; 67(14):1543-9. PubMed ID: 17705243
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Variations in blood ghrelin levels in prostate cancer patients submitted to hormone suppressive treatment.
    Bertaccini A; Pernetti R; Marchiori D; Pagotto U; Palladoro F; Palmieri F; Vitullo G; Guidi M; Martorana G
    Anticancer Res; 2009 Apr; 29(4):1345-8. PubMed ID: 19414385
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Prostate and hormone replacement therapy].
    Pompeo AC; Damião R; Campos RM; Lopes EJ
    Int Braz J Urol; 2006; 32 Suppl 1():35-8. PubMed ID: 23631040
    [No Abstract]   [Full Text] [Related]  

  • 50. Testosterone replacement therapy and the risk of prostate cancer: a perspective view.
    Barqawi AB; Crawford ED
    Int J Impot Res; 2005; 17(5):462-3. PubMed ID: 15889127
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy.
    Elmansy HM; Elzayat EA; Sampalis JS; Elhilali MM
    Urology; 2009 Nov; 74(5):1105-10. PubMed ID: 19773035
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Significance of prostate-specific antigen-doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: analysis on 56 cases of cancer-specific death.
    Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
    Int J Urol; 2007 Feb; 14(2):123-7. PubMed ID: 17302568
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.
    Heng DY; Chi KN
    Can J Urol; 2006 Dec; 13(6):3335-9. PubMed ID: 17187697
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Quantitative changes of testosterone and prostate-specific antigen at low and high densities of PSA in men with prostate cancer].
    Khuskivadze AA; Kochiashvili DK
    Georgian Med News; 2007 Feb; (143):67-9. PubMed ID: 17404444
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.
    Sartor O
    J La State Med Soc; 2008; 160(2):99-100. PubMed ID: 18681353
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcome analysis of prostate cancer patients with pre-treatment PSA greater than 50 ng/ml.
    Wiebe E; Rodrigues G; Lock M; D'Souza D; Stitt L
    Can J Urol; 2008 Jun; 15(3):4078-83. PubMed ID: 18570713
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A G/A polymorphism in the androgen response element 1 of prostate-specific antigen gene correlates with the response to androgen deprivation therapy in Japanese population.
    Shibahara T; Onishi T; Franco OE; Arima K; Nishikawa K; Yanagawa M; Hioki T; Watanabe M; Hirokawa Y; Shiraishi T; Sugimura Y
    Anticancer Res; 2006; 26(5A):3365-71. PubMed ID: 17094454
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prostate-specific antigen (PSA) and PSA velocity: competitors or collaborators in the prediction of curable and clinically significant prostate cancer.
    D'Amico AV
    J Clin Oncol; 2008 Feb; 26(6):823-4. PubMed ID: 18281649
    [No Abstract]   [Full Text] [Related]  

  • 60. Testosterone replacement therapy in hypogonadal men and prostate cancer risk.
    Kirby R; Gould D
    BJU Int; 2005 Sep; 96(4):471-2. PubMed ID: 16104891
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.